Cargando…

Ceftriaxone+Sulbactam+Disodium EDTA Versus Meropenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: PLEA, a Double-Blind, Randomized Noninferiority Trial

BACKGROUND: CSE is a novel combination of ceftriaxone, sulbactam, and disodium ethylenediaminetetraacetic acid (EDTA) with activity against multidrug-resistant Gram-negative pathogens. METHODS: Adult patients aged ≥18 years with a diagnosis of complicated urinary tract infections (cUTIs), including...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mir, Mohd Amin, Chaudhary, Saransh, Payasi, Anurag, Sood, Rajeev, Mavuduru, Ravimohan S, Shameem, Mohd
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767967/ https://www.ncbi.nlm.nih.gov/pubmed/31433059 http://dx.doi.org/10.1093/ofid/ofz373

Ejemplares similares

1974. Ceftriaxone-Sulbactam-EDTA vs. Meropenem in PLEA (a Phase 3, Randomized, Double-Blind Trial): Outcomes by Baseline MIC in Adults With Complicated Urinary Tract Infections or Acute Pyelonephritis
por: Mandale, Pankaj, et al.
Publicado: (2018)

1959. Ceftriaxone-Sulbactam-EDTA (CSE) vs. Meropenem (MR) in PLEA (a Phase 3, Randomized, Double-Blind Trial): Outcomes in Patients Infected With Ceftriaxone Non-Susceptible, Extended-Spectrum β-Lactamase and Multi-Drug-resistant Pathogens at Baseline
por: Mir, Mohd Amin, et al.
Publicado: (2018)

1984. Ceftriaxone-Sulbactam-EDTA vs. Meropenem: Analysis of Failed Patients With Assessment of MIC Increases and Changes in Genotypic Profile in PLEA (a Phase 3, Randomized, Double-Blind Clinical Trial in Adults With Complicated Urinary Tract Infections or Acute Pyelonephritis)
por: Mir, Mohd Amin, et al.
Publicado: (2018)

1373. Activity of Ceftriaxone–Sulbactam–EDTA Against Multi-Drug-resistant A. baumannii, P. aeruginosa and Enterobacteriaceae Isolates (WHO Critical Priority Pathogens) Collected from Various Hospitals in India
por: Girotra, Ruchi, et al.
Publicado: (2018)

381. Effect of Ceftriaxone+sulbactam+disodium EDTA Combination in Treatment of Complicated Urinary Tract Infections Caused by Metallo Beta-lactamase Producing Enterobacterales: An Open Label Randomized Controlled Trial
por: Samantaray, Subhashree, et al.
Publicado: (2023)

Safety and efficacy of a novel drug elores (ceftriaxone + sulbactam + disodium edetate) in the management of multi-drug resistant bacterial infections in tertiary care centers: a post-marketing surveillance study
por: Chaudhary, Manu, et al.
Publicado: (2017)

Evaluation of ceftriaxone-sulbactam-disodium edetate adjuvant combination against multi-drug resistant Gram-negative organisms
por: Gupta, Shilpi, et al.
Publicado: (2020)

A Validated Reverse Phase HPLC Method for the Determination of Disodium EDTA in Meropenem Drug Substance with UV-Detection using Precolumn Derivatization Technique
por: Narola, Bhavil, et al.
Publicado: (2011)

Comparison of different ratios of cefoperazone/sulbactam in patients with pyelonephritis
por: Jiang, Weizhong, et al.
Publicado: (2023)

A Comparative In Vitro Sensitivity Study of “Ceftriaxone–Sulbactam–EDTA” and Various Antibiotics against Gram-negative Bacterial Isolates from Intensive Care Unit
por: Singh, Sweta, et al.
Publicado: (2020)

Polymyxin B-Induced Kidney Injury Assessment of a Novel Formulation of Polymyxin B (VRP-034) in Rats
por: Roy, Dilip, et al.
Publicado: (2021)

A Novel High Performance Liquid Chromatographic Method for Simultaneous Determination of Ceftriaxone and Sulbactam in Sulbactomax
por: Shrivastava, Sanjay Mohan, et al.
Publicado: (2009)

A multicentre clinical study on the injection of ceftriaxone/sulbactam compared with cefoperazone/sulbactam in the treatment of respiratory and urinary tract infections
por: Xin, Xiaojuan, et al.
Publicado: (2013)

An In Vitro Susceptibility Study of Cefotaxime-Sulbactam on Clinical Bacterial Isolates From Various Regions in India: A Comparison With Ceftriaxone-Sulbactam
por: Gondane, Ajitkumar A, et al.
Publicado: (2023)

P05 In vivo efficacy of VRP-034 in lung and thigh infection models
por: Vishwakarma, Kamlesh Kumar, et al.
Publicado: (2022)

Protective role of ceftriaxone plus sulbactam with VRP1034 on oxidative stress, hematological and enzymatic parameters in cadmium toxicity induced rat model
por: Dwivedi, Vivek Kumar, et al.
Publicado: (2012)

In Vitro Susceptibility of Clinical Isolates to Ceftriaxone Alone and Ceftriaxone in Combination With Sulbactam or Tazobactam: A Comparative Study of Broad-Spectrum β-Lactam Antibiotics in India
por: Sanghavi, Sonali, et al.
Publicado: (2023)

Metabolomic profiling of polymyxin-B in combination with meropenem and sulbactam against multi-drug resistant Acinetobacter baumannii
por: Zhu, Shixing, et al.
Publicado: (2022)

Long-term stability of gentamicin sulfate-ethylenediaminetetraacetic acid disodium salt (EDTA-Na(2)) solution for catheter locks
por: Fiolet, Anne-Sophie, et al.
Publicado: (2018)

Genomic Background and Phylogeny of cfiA-Positive Bacteroides fragilis Strains Resistant to Meropenem-EDTA
por: Valdezate, Sylvia, et al.
Publicado: (2021)

Activity of Imipenem, Meropenem, Cefepime, and Sulbactam in Combination with the β-Lactamase Inhibitor LN-1-255 against Acinetobacter spp.
por: Lasarte-Monterrubio, Cristina, et al.
Publicado: (2021)

2138. In Vitro Susceptibility of Recent Clinical Isolates of P. aeruginosa and Enterobacterales to Imipenem or Meropenem Alone or in Combination with Sulbactam-Durlobactam
por: McLeod, Sarah, et al.
Publicado: (2023)

Comparison between Ceftriaxone and Sulbactam-Ampicillin as Initial Treatment of Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis
por: Kato, Hideo, et al.
Publicado: (2022)

The combination effect of meropenem/sulbactam/polymyxin-B on the pharmacodynamic parameters for mutant selection windows against carbapenem-resistant Acinetobacter baumannii
por: Zhang, Jiayuan, et al.
Publicado: (2022)

Pharmacokinetics and Tolerability of Intravenous Sulbactam-Durlobactam with Imipenem-Cilastatin in Hospitalized Adults with Complicated Urinary Tract Infections, Including Acute Pyelonephritis
por: Sagan, Olexiy, et al.
Publicado: (2020)

In vivo efficacy & resistance prevention of cefiderocol in combination with ceftazidime/avibactam, ampicillin/sulbactam or meropenem using human-simulated regimens versus Acinetobacter baumannii
por: Gill, Christian M, et al.
Publicado: (2023)

1042 Prevalence of Fluoroquinolone- and Ceftriaxone-resistant E. coli among U.S. Emergency Department Patients with Acute Pyelonephritis
por: Moran, Gregory, et al.
Publicado: (2014)

Emphysematous pyelonephritis
por: Yadav, Navin Kumar, et al.
Publicado: (2020)

Defining the noninferiority margin and analysing noninferiority: An overview
por: Althunian, Turki A., et al.
Publicado: (2017)

Comparison in a rat thigh abscess model of imipenem, meropenem and cefoperazone-sulbactam against Acinetobacter baumannii strains in terms of bactericidal efficacy and resistance selection
por: Fetiye, Kolayli, et al.
Publicado: (2004)

RE: Emphysematous pyelonephritis: Is nephrectomy warranted?
por: Kamarulzaman, Mohd. Nazli, et al.
Publicado: (2016)

Pan-ureteric transitional cell carcinoma in a patient of autosomal dominant polycystic kidney disease with chronic renal failure
por: Kumar, Santosh, et al.
Publicado: (2009)

Robot-assisted pyeloplasty for pelvi-ureteric junction obstruction of lower moiety in partial duplex system: A technical challenge
por: Bora, Girdhar S., et al.
Publicado: (2016)

Whole genome sequencing and in vitro activity data of Escherichia phage NTEC3 against multidrug-resistant Uropathogenic and extensively drug-resistant Uropathogenic E. coli isolates
por: Chaudhary, Naveen, et al.
Publicado: (2022)

Disodium 4,4′-oxydibenzoate
por: Yang, Yuan, et al.
Publicado: (2008)

Population Pharmacokinetics and Dosing Simulations of Ampicillin and Sulbactam in Hospitalised Adult Patients
por: Setiawan, Eko, et al.
Publicado: (2023)

Complete Genome Sequence of Escherichia Phage 590B, Active against an Extensively Drug-Resistant Uropathogenic Escherichia coli Isolate
por: Chaudhary, Naveen, et al.
Publicado: (2021)

Conservative management of emphysematous pyelonephritis
por: Laway, Bashir Ahmad, et al.
Publicado: (2012)

1228. Outcomes Associated with Empiric Cefepime or Meropenem for Bloodstream Infections Caused by Ceftriaxone-Resistant, Cefepime-Susceptible Escherichia coli and Klebsiella pneumoniae
por: Frescas, Brian E, et al.
Publicado: (2021)

Noninferiority trials
por: Snapinn, Steven M
Publicado: (2000)

Cannot write session to /tmp/vufind_sessions/sess_04scgpppvhavco2r28astsatoq